Update of drug-resistant tuberculosis treatment guidelines: A turning point
International Journal of Infectious Diseases·
- DOI
- 10.1016/j.ijid.2023.03.013
- PMID
- 36918080
- PMCID
- —
- OpenAlex
- W4323975519
- Study type
- Guideline
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The updated guidelines establish a shorter, all-oral, and more patient-centered approach to MDR/RR-TB management, potentially improving treatment acceptability and equity.
Structured evidence summary
Research question
This guideline update addresses treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis, focusing on shorter all-oral options.
Study design
WHO treatment guideline released in December 2022, presenting evidence-based recommendations for MDR/RR-TB management.
Population and setting
Patients with multidrug-resistant or rifampicin-resistant tuberculosis, including those with extensive pulmonary disease and selected forms of extrapulmonary tuberculosis.
Main findings
A 6-month regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin is now recommended for MDR/RR-TB patients, expanding to include extensive pulmonary and most extrapulmonary forms. A 9-month all-oral regimen is suggested when fluoroquinolone resistance is excluded. Longer 18-month treatments remain indicated when shorter regimens cannot be used due to intolerance, drug interactions, extensive drug resistance, or specific disease presentations.
Public-health relevance
The updated guidelines establish a shorter, all-oral, and more patient-centered approach to MDR/RR-TB management, potentially improving treatment acceptability and equity.
Important limitations
Implementation challenges remain unspecified in the abstract. This summary relies on the supplied single-article abstract and metadata; the original guideline document is required for decision-grade interpretation of eligibility criteria, contraindications, and implementation considerations.
GIDS interpretation
This document is discoverable through disease classification for tuberculosis and topic classification for antimicrobial resistance, health policy, and treatment. It represents policy guidance rather than primary research on disease emergence or transmission.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.